Personalized therapy in early breast cancer. Practical implications

被引：3

作者：

Acevedo, Francisco ^{[1
]}

Sanchez, Cesar ^{[1
]}

Walbaum, Benjamin ^{[1
]}

机构：

[1] Pontificia Univ Catolica Chile, Dept Hematol Oncol, Santiago, Chile

来源：

REVISTA MEDICA CLINICA LAS CONDES | 2022年 / 33卷 / 01期

关键词：

Breast Neoplasm; Precision Medicine; Genomics; Proteomics; MOLECULAR PORTRAITS; MONOCLONAL-ANTIBODY; TREATMENT DECISIONS; 70-GENE SIGNATURE; GENE-EXPRESSION; NEOADJUVANT; CHEMOTHERAPY; SUBTYPES; RISK; AMPLIFICATION;

D O I：

10.1016/j.rmclc.2021.12.002

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Breast cancer is the most frequent cancer in Chile and the world. The development of systemic treatments has considerably improved breast cancer survival. Since the discovery of the estrogen receptor more than 50 years ago, much progress has been made in understanding the heterogeneity of this disease. Advances in our understanding of proteomics, genomics, and cancer biology have led to a deeper appreciation of the complexity and variability of the genes involved and their phenotypic representation. Consequently, the treatment of these patients has become increasingly individualized and precise. Nothing better to exemplify this than what has happened in breast cancer: easy to use clinical biomarkers with proven prognostic and predictive utility have led the way in how cancer should be treated in general. In the next article we will try to describe this path, we will show the meaning and potential implications of intrinsic subgroups, the use of genomic platforms to define more individualized treatments and how the future is going to be shaped by precision therapy in cancer. The goal is to provide an overview of how precision medicine has impacted the management of early breast cancer.

引用

页码：17 / 24

页数：8

共 48 条

[1]

Beatson George T, 1896, Trans Med Chir Soc Edinb, V15, P153

[2] CORRELATION OF ESTROPHILIN CONTENT OF PRIMARY MAMMARY-CANCER TO EVENTUAL ENDOCRINE TREATMENT [J].

BLOCK, GE ;

ELLIS, RS ;

DESOMBRE, E ;

JENSEN, E .

ANNALS OF SURGERY, 1978, 188 (03) :372-376

[3]

Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI [10.3322/caac.21492, 10.3322/caac.21609]

[4] Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes A Meta-Analysis [J].

Broglio, Kristine R. ;

Quintana, Melanie ;

Foster, Margaret ;

Olinger, Melissa ;

McGlothlin, Anna ;

Berry, Scott M. ;

Boileau, Jean-Francois ;

Brezden-Masley, Christine ;

Chia, Stephen ;

Dent, Susan ;

Gelmon, Karen ;

Paterson, Alexander ;

Rayson, Daniel ;

Berry, Donald A. .

JAMA ONCOLOGY, 2016, 2 (06) :751-760

[5] Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer [J].

Burstein, Matthew D. ;

Tsimelzon, Anna ;

Poage, Graham M. ;

Coyington, Kyle R. ;

Contreras, Alejandro ;

Fuqua, Suzanne A. W. ;

Sayage, Michelle I. ;

Osborne, C. Kent ;

Hilsenbeck, Susan G. ;

Chang, Jenny C. ;

Mills, Gordon B. ;

Lau, Ching C. ;

Brown, Powel H. .

CLINICAL CANCER RESEARCH, 2015, 21 (07) :1688-1698

[6] 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer [J].

Cardoso, F. ;

van't Veer, L. J. ;

Bogaerts, J. ;

Slaets, L. ;

Viale, G. ;

Delaloge, S. ;

Pierga, J. -Y. ;

Brain, E. ;

Causeret, S. ;

DeLorenzi, M. ;

Glas, A. M. ;

Golfinopoulos, V. ;

Goulioti, T. ;

Knox, S. ;

Matos, E. ;

Meulemans, B. ;

Neijenhuis, P. A. ;

Nitz, U. ;

Passalacqua, R. ;

Ravdin, P. ;

Rubio, I. T. ;

Saghatchian, M. ;

Smilde, T. J. ;

Sotiriou, C. ;

Stork, L. ;

Straehle, C. ;

Thomas, G. ;

Thompson, A. M. ;

van der Hoeven, J. M. ;

Vuylsteke, P. ;

Bernards, R. ;

Tryfonidis, K. ;

Rutgers, E. ;

Piccart, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (08) :717-729

[7] Basal-like breast cancer defined by five biomarkers has superior prognostic value then triple-negative phenotype [J].

Cheang, Maggie C. U. ;

Voduc, David ;

Bajdik, Chris ;

Leung, Samuel ;

McKinney, Steven ;

Chia, Stephen K. ;

Perou, Charles M. ;

Nielsen, Torsten O. .

CLINICAL CANCER RESEARCH, 2008, 14 (05) :1368-1376

[8] Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [J].

Cortazar, Patricia ;

Zhang, Lijun ;

Untch, Michael ;

Mehta, Keyur ;

Costantino, Joseph P. ;

Wolmark, Norman ;

Bonnefoi, Herve ;

Cameron, David ;

Gianni, Luca ;

Valagussa, Pinuccia ;

Swain, Sandra M. ;

Prowell, Tatiana ;

Loibl, Sibylle ;

Wickerham, D. Lawrence ;

Bogaerts, Jan ;

Baselga, Jose ;

Perou, Charles ;

Blumenthal, Gideon ;

Blohmer, Jens ;

Mamounas, Eleftherios P. ;

Bergh, Jonas ;

Semiglazov, Vladimir ;

Justice, Robert ;

Eidtmann, Holger ;

Paik, Soonmyung ;

Piccart, Martine ;

Sridhara, Rajeshwari ;

Fasching, Peter A. ;

Slaets, Leen ;

Tang, Shenghui ;

Gerber, Bernd ;

Geyer, Charles E., Jr. ;

Pazdur, Richard ;

Ditsch, Nina ;

Rastogi, Priya ;

Eiermann, Wolfgang ;

von Minckwitz, Gunter .

LANCET, 2014, 384 (9938) :164-172

[9] The effects of population-based mammography screening starting between age 40 and 50 in the presence of adjuvant systemic therapy [J].

de Gelder, Rianne ;

Heijnsdijk, Eveline A. M. ;

Fracheboud, Jacques ;

Draisma, Gerrit ;

de Koning, Harry J. .

INTERNATIONAL JOURNAL OF CANCER, 2015, 137 (01) :165-172

[10] Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials [J].

Dowsett, M. ;

Forbes, J. F. ;

Bradley, R. ;

Ingle, J. ;

Aihara, T. ;

Bliss, J. ;

Boccardo, F. ;

Coates, A. ;

Coombes, R. C. ;

Cuzick, J. ;

Dubsky, P. ;

Gnant, M. ;

Kaufmann, M. ;

Kilburn, L. ;

Perrone, F. ;

Rea, D. ;

Thuerlimann, B. ;

van de Velde, C. ;

Pan, H. ;

Peto, R. ;

Davies, C. ;

Gray, R. ;

Baum, M. ;

Buzdar, A. ;

Sestak, I. ;

Markopoulos, C. ;

Fesl, C. ;

Jakesz, R. ;

Colleoni, M. ;

Gelber, R. ;

Regan, M. ;

von Minckwitz, G. ;

Snowdon, C. ;

Goss, P. ;

Pritchard, K. ;

Anderson, S. ;

Costantino, J. ;

Mamounas, E. ;

Ohashi, Y. ;

Watanabe, T. ;

Bastiaannet, E. .

LANCET, 2015, 386 (10001) :1341-1352

← 1 2 3 4 5 →